Adecatumumab

A recombinant human IgG1 monoclonal antibody (MoAb) directed against the tumor associated antigen (TAA) epithelial cell adhesion molecule (EpCAM… (More)

Topic mentions per year

Topic mentions per year

2006-2018
012320062018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
BACKGROUND Targeted therapy options in HER2-negative breast cancer are limited. This open-label, multicenter phase IB dose… (More)
Is this relevant?
2010
2010
BACKGROUND High-level expression of epithelial cell adhesion molecule (EpCAM) is associated with unfavorable prognosis in breast… (More)
Is this relevant?
2010
2010
We evaluated the expression of epithelial cell adhesion molecule (EpCAM) and the potential of MT201 (adecatumumab), a human… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • table 3
Is this relevant?
2010
2010
BACKGROUND Rising serum levels of prostate-specific antigen (PSA) after radical prostatectomy are indicative of recurrent… (More)
Is this relevant?
2010
2010
Epithelial cell adhesion molecule (EpCAM) is frequently and highly expressed on human carcinomas. The emerging role of EpCAM as a… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2010
2010
TO THE EDITOR: In their editorial, Schmoll and Arnold discussed possible reasons for the ultimate failure of anti– epithelial… (More)
Is this relevant?
2007
2007
Micromet Inc, in collaboration with Merck Serono SA, is developing adecatumumab for the potential treatment of adenocarcinomas… (More)
Is this relevant?
2007
2007
An important mode of action shared by human IgG1 antibody therapies is antibody-dependent cellular cytotoxicity (ADCC). ADCC… (More)
Is this relevant?
2006
2006
AIM OF THE STUDY Adecatumumab (also known as MT201) is a human recombinant IgG1 monoclonal antibody binding with low affinity to… (More)
Is this relevant?
2006
2006
A common feature of human IgG1 antibodies used for cancer treatment is that their anti-tumour efficacy requires high serum trough… (More)
Is this relevant?